Clinical Trials Browser

Phase 1/2 × Interventional × vandetanib × Clear all

NCT02495103 2021-01-26

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Phase 1/2 Terminated

7 enrolled 10 charts

Carcinoma, Renal Cell

NCT00514046 2020-12-22

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

Phase 1/2 Completed

17 enrolled 25 charts

Multiple Endocrine Neoplasia, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT00441142 2019-03-05

Zactima

Phase 1/2 Completed

119 enrolled 15 charts

Glioblastoma, Gliosarcoma

NCT00923247 2018-11-29

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Phase 1/2 Terminated

22 enrolled 21 charts

Neoplasms, Thyroid Neoplasms, Carcinoma, Medullary

NCT01661179 2016-12-05

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Phase 1/2 Completed

14 enrolled 7 charts

Neoplasm Metastasis, Carcinoma, Medullary

NCT00862836 2016-10-10

ZACFAST

Phase 1/2 Terminated

15 enrolled 13 charts

Ovarian Neoplasms